Trials / Completed
CompletedNCT05056246
Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants
A Phase I, Open-label, Randomized, Parallel-arm, Single-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study is to evaluate the pharmacokinetics (PK) of AMG 133 after single subcutaneous (SC) administration in healthy Japanese and Caucasian participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 133 | Solution for SC injection |
Timeline
- Start date
- 2021-09-10
- Primary completion
- 2022-04-08
- Completion
- 2022-04-08
- First posted
- 2021-09-24
- Last updated
- 2025-02-25
- Results posted
- 2025-02-25
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05056246. Inclusion in this directory is not an endorsement.